Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04526574 · ClinicalTrials.gov registry record · Phase 3
Safety and Immunogenicity of 20vPnC Coadministered With SIIV in Adults ≥65 Years of Age
A Phase 3 study, sponsored by Pfizer.
- Completed
- Registry status
- Phase 3
- Development phase
- 1,796
- Enrollment target
NCT04526574: Completed Phase 3 study, sponsored by Pfizer.
NCT04526574 is a Phase 3 study that has completed, run by Pfizer. The registered enrollment target is 1,796 participants, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (133% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04526574, a Phase 3 study, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 1,796 participants
- Enrollment target
Study Summary
Study of the safety and immunogenicity of 20vPnC and influenza vaccine administered at the same visit or separately
Primary Outcome
Local reactions were collected at the 20vPnC injection sites after Vaccination 1 and Vaccination 2 and were recorded by the participants using an electronic diary (e-diary). Local reactions included redness, swelling and pain at the injection site. Redness and swelling were measured and recorded in measuring device units. 1 measuring device unit =0.5 centimeter (cm). Redness and swelling were graded as mild (greater than \[\>\] 2.0 to 5.0 cm), moderate (\>5.0 to 10.0 cm) and severe (\>10.0 cm).
Interventions
- OTHER Saline
- BIOLOGICAL Influenza vaccine
- BIOLOGICAL Experimental 20-valent pneumococcal conjugate vaccine (20vPnC)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,796 participants |
| Start Date | 2020-09-01 |
| Est. Completion | 2021-06-29 |
| Phase | Phase 3 |
What the finished NCT04526574 record still lists
NCT04526574 is an interventional study that assigns participants to a tested intervention. Its 1,796 participants enrollment target places it among the larger protocols in the corpus, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (133% higher).
The record links to 0 conditions, and to 3 interventions - of which Saline is the first listed.
NCT04526574 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04526574 about?
NCT04526574 is a clinical study titled "Safety and Immunogenicity of 20vPnC Coadministered With SIIV in Adults ≥65 Years of Age". Study of the safety and immunogenicity of 20vPnC and influenza vaccine administered at the same visit or separately
What is the current status of trial NCT04526574?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 1,796 participants. The study started on 2020-09-01. Estimated completion is 2021-06-29.
What interventions are being tested in trial NCT04526574?
The interventions under investigation include: Saline (OTHER), Influenza vaccine (BIOLOGICAL), Experimental 20-valent pneumococcal conjugate vaccine (20vPnC) (BIOLOGICAL).
Who is sponsoring clinical trial NCT04526574?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04526574's enrollment target sits among peer trials
1,796 125th of 2000 higher than 1,876 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03630055 · 1,800 participants · Phase 3
Rivaroxaban Post-Transradial Access for the Prevention of Radial Artery Occlusion
- NCT04475640 · 1,800 participants · NA
Cancer Genetic Testing in Ethnic Populations
- NCT04980794 · 1,800 participants · NA
The Happy Families Project: Testing the Effectiveness of a Conflict Resolution Program for Families
- NCT05258656 · 1,800 participants · NA
Childhood Activities Nutrition and Development Oversight
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI